Formulation of MK2 inhibitor peptides

1. A pharmaceutical formulation for delivery by inhalation comprising a therapeutic amount of an MK2i polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, up to 5% solids before drying, 7.5% w/w and 20% w/w trehalose, and a pharmaceutically acceptable carrier, wherein the formulation is effective to preserve at least about 96% of physical, chemical, microbiological, therapeutic, and toxicological specifications of the MK2i polypeptide for at least 4 weeks at 25 C and bioavailability of the MK2i polypeptide.

2. The pharmaceutical formulation according to claim 1 , wherein the pharmaceutical formulation is a particulate pharmaceutical formulation.

3. The pharmaceutical formulation according to claim 1 , wherein the pharmaceutical formulation is an aerosolized pharmaceutical formulation.

4. The pharmaceutical formulation according to claim 1 , wherein the formulation is prepared by a process of spray drying.

5. The pharmaceutical formulation according to claim 2 , wherein the pharmaceutical formulation comprises 1% w/w solids before drying.

6. The pharmaceutical formulation according to claim 2 , wherein the pharmaceutical formulation comprises 5% w/w solids before drying.

7. The pharmaceutical formulation according to claim 1 , wherein the MK2i polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or the functional equivalent thereof and trehalose are in a ratio of 80/20 (% w/w) respectively.

8. The pharmaceutical formulation according to claim 1 , wherein the MK2i polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or the functional equivalent thereof and trehalose are in a ratio of 92.5/7.5 (% w/w) respectively.

9. The pharmaceutical formulation according to claim 1 , wherein the functional equivalent is made from a fusion between a first polypeptide that is a protein transduction domain (PTD) and a second polypeptide that is a therapeutic domain (TD).

10. The pharmaceutical formulation according to claim 9 , wherein the protein transduction domain (PTD) is selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 11), FAKLAARLYR (SEQ ID NO: 16), and KAFAKLAARLYR (SEQ ID NO: 17), and a second polypeptide that is a therapeutic domain (TD) of amino acid sequence KALARQLGVAA (SEQ ID NO: 2).

11. The pharmaceutical formulation according to claim 1 , wherein the pharmaceutical formulation is delivered to a subject via a dry powder inhalation device (DPI).

12. The pharmaceutical formulation according to claim 3 further comprising saline before drying.

13. The pharmaceutical formulation according to claim 12 , wherein the saline is NaCl.

14. The pharmaceutical formulation according to claim 3 , wherein the functional equivalent is made from a fusion between a first polypeptide that is a protein transduction domain (PTD) and a second polypeptide that is a therapeutic domain (TD).

15. The pharmaceutical formulation according to claim 14 , wherein the protein transduction domain (PTD) is selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 11), FAKLAARLYR (SEQ ID NO: 16), and KAFAKLAARLYR (SEQ ID NO: 17), and a second polypeptide that is a therapeutic domain (TD) of amino acid sequence KALARQLGVAA (SEQ ID NO: 2).

16. The pharmaceutical formulation according to claim 1 , comprising an ionic complex of the MK2i polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof and a nano-polyplex polymer, wherein the ionic complex dissociates in intracellular compartments selected by intracellular pH conditions such that bioactivity and stability of the peptide is preserved.

17. The pharmaceutical formulation according to claim 16 , wherein the nano-polyplex polymer is anionic and endosomolytic.

18. The pharmaceutical formulation according to claim 17 , wherein the nano-polyplex polymer is poly(propylacrylic acid) (PPAA).

19. The pharmaceutical formulation according to claim 18 , wherein the pharmaceutical formulation comprises a charge ratio (CR) of the MK2i polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof to PPAA selected from the group consisting of 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 and 1:10.

20. The pharmaceutical formulation according to claim 19 , wherein the charge ratio (CR) is 1:3.

21. The pharmaceutical formulation according to claim 17 , wherein the nano-polyplex polymer is poly(acrylic acid) (PAA).

22. The pharmaceutical formulation according to claim 16 , wherein the functional equivalent is made from a fusion between a first polypeptide that is a protein transduction domain (PTD) and a second polypeptide that is a therapeutic domain (TD).

23. The pharmaceutical formulation according to claim 22 , wherein the protein transduction domain (PTD) is selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 11), FAKLAARLYR (SEQ ID NO: 16), and KAFAKLAARLYR (SEQ ID NO: 17), and a second polypeptide that is a therapeutic domain (TD) of amino acid sequence KALARQLGVAA (SEQ ID NO: 2).

24. The pharmaceutical formulation according to claim 16 , wherein the pharmaceutical formulation is delivered to a subject via an implantation device.

25. The pharmaceutical formulation according to claim 16 , wherein the pharmaceutical formulation is delivered to a subject topically.

26. The pharmaceutical formulation according to claim 16 , wherein the pharmaceutical formulation is delivered to a subject parenterally.

27. A method for treating a vascular graft-induced intimal hyperplasia in a subject in need of such treatment, the method comprising administering the pharmaceutical formulation of claim 20 comprising a therapeutic amount of a polypeptide of amino sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof, and a nano-polyplex polymer, wherein the therapeutic amount is effective to inhibit MK2; and to treat a vascular graft-induced intimal hyperplasia.

28. The method according to claim 27 , wherein the nano-polyplex polymer is anionic and endosomolytic.

29. The method according to claim 28 , wherein the nano-polyplex polymer is poly(propylacrylic acid) (PPAA).

30. The method according to claim 27 , wherein the pharmaceutical formulation comprises a charge ratio (CR) of the polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA; SEQ ID NO: 1 or a functional equivalent thereof to PPAA selected from the group consisting of 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:1.5, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9 and 1:10.

31. The method according to claim 30 , wherein the charge ratio (CR) is 1:3.

32. The method according to claim 28 , wherein the nano-polyplex polymer is poly(acrylic acid) (PAA).

33. The method according to claim 27 , wherein the functional equivalent is made from a fusion between a first polypeptide that is a protein transduction domain (PTD) and a second polypeptide that is a therapeutic domain (TD).

34. The method according to claim 33 , wherein the protein transduction domain (PTD) is selected from the group consisting of a polypeptide of amino acid sequence YARAAARQARA (SEQ ID NO: 11), FAKLAARLYR (SEQ ID NO: 16), and KAFAKLAARLYR (SEQ ID NO: 17), and a second polypeptide that is a therapeutic domain (TD) of amino acid sequence KALARQLGVAA (SEQ ID NO: 2).

35. The method according to claim 27 , wherein the administering is by an implantation device.

36. The method according to claim 27 , wherein the administering is by topical administration.

37. The method according to claim 27 , wherein the administering is by parenteral administration.